Clinical control study on liposomes of alprostadil combined with huangqi injection in treatment of hepatorenalsyndrome
10.3760/cma.j.issn.1673-4904.2011.31.005
- VernacularTitle:前列地尔脂质体联合黄芪注射液治疗肝肾综合征的临床对照研究
- Author:
Miaoguo XU
- Publication Type:Journal Article
- Keywords:
Hepatorenal syndrome;
Alprostadil;
Astragalus membranaceus
- From:
Chinese Journal of Postgraduates of Medicine
2011;34(31):12-15
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical curative effects on liposomes of alprostadil (Lipo PGE1)combined with huangqi injection in the treatment of the patients with hepatorenal syndrome (HRS).Methods Retrospective analysis was made on 26 patients with HRS Ⅱ (treatment group) who were treated with Lipo PGE1 combined with huangqi injection,and compared with 28 patients (control group) whoreceived normal liver protection,diuretics,symptomatic and supporting treatment.Results Total effective rate in treatment group [ 88.5％ (23/26) ] was significantly higher than that in control group [ 64.3％ ( 18/28 ) ](P ＜ 0.05 ).After treatment,alanine aminotransferase (ALT),total bilirubin (TBIL),prothrombin activity ( PTA ) were significantly improved compared with before treatment in two groups(P ＜ 0.05 ).After treatment,ALT,PTA had significant difference in two groups (P＜ 0.05 ),and TBIL had no significant difference in two groups (P＞0.05).Creatinine clearance rate(CCr),blood urea nitrogen(BUN),serum creatinine(SCr) and 24 hours urinary protein quantitative defermination was significantly improved in two groups after treatment (P ＜ 0.05 ),and the degree of improvement had significant difference (P ＜ 0.05 ).Conclusion Lipo PGE1 combined with huangqi injection in treating the patients with HRS can significantly improve the clinical curative effects,restore renal and liver function,and should be used in clinical work.
